Showing results 485 to 504 of 918
< previous
next >
| Preview | Issue Date | Title | Author(s) |
| 2013 | Ketamine as a new treatment for depression: a review of its efficacy and adverse effects | Katalinic, K.; Lai, R.; Somogyi, A.; Mitchell, P.; Glue, P.; Loo, C. |
| 2008 | Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV/AIDS | Lawrinson, P.; Ali, R.; Buarvirat, A.; Chiamwongpaet, S.; Dvoryak, S.; Habrat, B.; Jie, S.; Mardiati, R.; Mokir, A.; Moskalewicz, J.; Newcombe, D.; Poznyak, V.; Subata, E.; Uchtenhagen, A.; Utami, D.; Vial, R.; Zhao, C. |
| 2000 | Kinetics and inhibition of the formation of 6β-naltrexol from naltrexone in human liver cytosol | Porter, S.; Somogyi, A.; White, J. |
| 2009 | LAAM in the treatment of opioid dependence: a systematic review | Clark, N.; Gijsbers, A.; White, Jason Mark |
| 2009 | Lack of association between the A118G polymorphism of the mu opioid receptor gene (OPRMI) and opioid defendence: A meta-analysis | Coller, J.; Beardsley, J.; Bignold, J.; Li, Y.; Merg, F.; Sullivan, T.; Cox, T.; Somogyi, A. |
| 2001 | Lack of effect of citalopram on the steady-state pharmacokinetics of carbamazepine in healthy male subjects | Moller, S.; Larsen, F.; Khant, A.; Rolan, P. |
| 1995 | Lack of effect of gender and oral contraceptive steroids on the pharmacokinetics of (R)-ibuprofen in human. | Knights, K.; McLean, C.; Tonkin, A.; Miners, J. |
| 2007 | Lack of influence of CYP2D6 genotype on the clearance of (R)- (S)- and racemic-methadon | Coller, J.; Joergensen, C.; Foster, D.; James, H.; Gillis, D.; Christrup, L.; Somogyi, A. |
| 2003 | Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjects | Ferron, G.; Patat, A.; Parks, V.; Rolan, P.; Troy, S. |
| 1998 | Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of a routine service | Morris, R.; Black, A.; Harris, A.; Batty, A.; Sallustio, B. |
| 2004 | Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity | Coller, J.; Krebsfaenger, N.; Klein, K.; Wolbold, R.; Nussler, A.; Neuhaus, P.; Zanger, U.; Eichelbaum, M.; Murdter, T. |
| 2021 | Large variability in plasma efavirenz concentration in Papua New Guinea HIV/AIDS patients associated with high frequency of CYP2B6 516T allele | Bordin Andriguetti, N.; Van Schalkwyk, H.K.; Barratt, D.T.; Tucci, J.; Pumuye, P.; Somogyi, A.A. |
| 1999 | Laws applying to minor cannabis offences in Australia and their evaluation | Lenton, S.; McDonald, D.; Ali, R.; Moore, T. |
| 2005 | LC mass spectrometry | Morris, R.; Taylor, P. |
| 2010 | LC-MS/MS for immunosuppressant therapeutic drug monitoring | Sallustio, B. |
| 2014 | Lethal hepatocellular necrosis associated with herbal polypharmacy in a patient with chronic hepatitis B infection | Gilbert, J.; Musgrave, I.; Hoban, C.; Byard, R. |
| 2018 | LiMA: a study protocol for a randomised, double-blind, placebo controlled trial of lisdexamfetamine for the treatment of methamphetamine dependence | Ezard, N.; Dunlop, A.; Hall, M.; Ali, R.; McKetin, R.; Bruno, R.; Phung, N.; Carr, A.; White, J.; Clifford, B.; Liu, Z.; Shanahan, M.; Dolan, K.; Baker, A.L.; Lintzeris, N. |
| 2009 | Limited uptake of the cyanobacterial toxin cylindrospermopsin by Vero cells | Froscio, S.; Cannon, E.; Lau, H.; Humpage, A. |
| 2007 | 'Listening' and 'talking' to neurons: Implications of immune activation for pain control and increasing the efficacy of opioids | Watkins, L.; Hutchinson, M.; Milligan, E.; Maier, S. |
| 2014 | Localization of relaxin receptors in arteries and veins, and region-specific increases in compliance and bradykinin-mediated relaxation after in vivo serelaxin treatment | Jelinic, M.; Leo, C.H.; Post Uiterweer, E.D.; Sandow, S.L.; Gooi, J.H.; Wlodek, M.E.; Conrad, K.P.; Parkington, H.; Tare, M.; Parry, L.J. |
